** Shares of Hansoh Pharmaceutical Group 3692.HK rise 3.8% to HK$27.5, their highest levels since August 2021
** Stock marks biggest intraday pct gain since May 20, and on track for a third straight session of rise, if current trend holds
** Stock is fifth-biggest pct gainer on the Hang Seng Commerce & Industry Index .HSNC, which climbs 0.8%
** Hansoh says its innovative drug Aumolertinib Mesilate Tablets for lung cancer has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for marketing
** The Hang Seng Biotech Index .HSHKBIO rises 3.1% and the Hang Seng Index .HSI adds 0.5%
** YTD, stock up 56.8%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。